Resistance profiles by drug class and drug

Information on drug class and individual drug resistance patterns was drawn from "HIV Drug Resistance Mutations by Drug Class," June 2008, produced by the Stanford HIV Drug Resistance Database at http://hivdb.stanford.edu, the IAS-USA Spring 2008 update of drug resistance mutation, available at www.iasusa.org/resistance_mutations, and the International AIDS Society-USA Panel 2008 recommendations for antiretroviral drug resistance testing, available online at www.journals.uchicago.edu/doi/full/10.1086/589297.1

Information on resistance mutations is updated regularly, so for the most complete information on drug resistance mutations, it is best to access directly the Stanford University and IAS-USA websites.

References

  1. Hirsch MS et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Inf Dis 47: 266-285, 2008
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.